As the world’s largest voluntary health agency dedicated to fighting blood cancers, The Leukemia & Lymphoma Society® (LLS) is leading the offensive to dramatically improve outcomes for patients with acute myeloid leukemia (AML), one of the most lethal blood cancers. LLS began funding AML research more than 66 years ago, and in the past five years alone we have invested nearly $100 million in AML research, with a focus on understanding the underlying causes of the disease to develop better therapies and save more lives. We are on the verge of realizing new hope for AML patients, who have not seen an advance in treatment in almost 40 years. LLS is uniquely qualified to change the landscape for patients with blood cancers, and other cancers, as we act as a catalyst for collaboration among medical centers, government, academia, and industry to advance the science on behalf of patients. Our mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. We fund lifesaving blood cancer research around the world and provide free information and support services for blood cancer patients seeking access to quality, affordable, coordinated care. Founded in 1949 and headquartered in Rye Brook, New York, LLS has chapters throughout the United States and Canada. To learn more, visit www.lls.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.